Click here to learn more

Scroll over the words in bold for brief definitions.

About ILARIS®

ILARIS®—A Specific Treatment for Cryopyrin-Associated Periodic Syndromes (CAPS)

In June 2009, ILARIS® (canakinumab) was approved in the United States for the treatment of Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), 2 conditions in a group of diseases called CAPS, in adults and in children aged 4 years and older.

ILARIS® is the first and only CAPS treatment that is approved for use in both adult patients and pediatric patients aged 4 years and older.

ILARIS® is a monoclonal antibody that binds to interleukin-1 beta (IL-1β) that reduces IL-1β-mediated inflammation.1-3 ILARIS® delivers a complete and sustained response in CAPS to benefit patients.4,5

  • 97% of CAPS patients achieved complete response by Week 8. 71% achieved complete response in just 7 days4,5
  • Complete response was defined as ratings of minimal or absent for physician's assessment of disease activity and assessment of skin disease and C-reactive protein (CRP) or serum amyloid A (SAA) values <10 mg/L4,5
  • A disease flare was defined as a CRP and/or SAA values >30 mg/L and either a score of mild or worse for disease activity or a score of minimal or worse for disease activity and skin disease4,5

Indication

ILARIS® (canakinumab) is an interleukin-1β blocker indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children aged 4 years and older including:

The following links may help you learn more about CAPS and how ILARIS® can help:

How to Prescribe ILARIS® to Your Patients

ILARIS® (canakinumab) is only available through a specialty pharmacy provider network. Prescribing ILARIS® for your patients is easy with the ILARIS® Patient Support Program

  • Step 1. Simply download the ILARIS® Request Form
  • Step 2. Complete the form and review it with your patient
  • Step 3. Fax the signed form back to 1-866-972-8316 to enroll patients in the ILARIS® Patient Support Program.

Stay Up to Date

Take a moment to register for ILARIS® Direct to have news and updates about ILARIS® sent directly to you.

Register

ILARIS® Patient Support Program

The ILARIS® Patient Support Program provides patients with information and tools to assist in managing their treatment with ILARIS® and helps to identify resources that can assist with payment for their medication.
Learn More

Register for ILARIS Updates

Sign up here for ILARIS® Direct and stay current with news about ILARIS®.
Register

Prescribe ILARIS® for your patients with CAPS.

ILARIS® Physician Brochure

This downloadable resource provides physicians with an overview of CAPS and demonstrates how ILARIS® can help patients suffering from CAPS.

Download Now

CAPS Signs and Symptoms Assessment

A brief assessment that can be referenced in-office when seeing patients. If a patient experiences any of these signs or symptoms on an ongoing basis, a diagnosis of CAPS may be considered.

Download Now

Note: The resource above may require Adobe® Acrobat® Reader for viewing and printing.


References:

  • 1. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity. 2004;20:319-325.
  • 2. Toker O, Hashkes PJ. Prevalence of Cryopyrin-Associated Periodic Syndrome (CAPS) Biologics. 2010;4:131-138.
  • 3. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet. 2001;29:301-305.
  • 4. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al; for the Canakinumab in CAPS Study Group. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med. 2009;360:2416-2425.
  • 5. Ilaris [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.


isi-Professional www.fda.gov/medwatch full prescribing information